LENZ Therapeutics, Inc. LENZ 深 滬
等待開盤 02-07 09:30:00 美东时间
14.22
+0.250
+1.79%
華盛通- 最 高15.04
- 今 開14.27
- 成交量 85.87万股
- 最 低 13.73
- 昨 收 13.97
- 總市值 4.45亿
- 52周最高 50.40
- 市盈率 靜 --
- 換手率 2.74%
- 52周最低 13.73
- 委 比 -91.93%
- 總股本 3129.00万
- 歷史最高 230.79
- 量 比 0.71
- 振 幅 9.38%
- 歷史最低 3.92
- 每 手 1
- 風險率 7.87%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多New FDA-Approved Eye Drop Sparks Fresh Competition For LENZ Therapeutics' Drug
FDA approved Tenpoint's Yuvezzi eye drop for presbyopia, adding competition for LENZ's VIZZ as analysts say the recent stock drop may be overdone and see blockbuster potential ahead.
01-31 02:02
LENZ Therapeutics Reports VIZZ Net Product Revenue Of ~ $1.6M In Q4 2025; Over 20,000 Prescriptions Filled Through Q4 2025; Rapid Uptake By Prescribing ECPs With Over 6,500 Unique Prescribing ECPs; More Than 55% Prescribed Multiple Times In Q4 2025
LENZ Therapeutics, Inc. (NASDAQ:LENZ), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment
01-08 06:15
LENZ Therapeutics Acknowledges Adverse Event Reported To FDA; Says Patient Using VIZZ Experiences Retinal Tear, Cause Uncertain Due To Pre-Existing Risk Factors
LENZ Therapeutics, Inc. ("the Company") is aware of a recent adverse event report submitted to the U.S. Food and Drug Administration's ("FDA") Adverse Event Reporting System ("FAERS") database describing a retinal tear
2025-12-13 05:29
LENZ Therapeutics And Lotus Pharmaceutical Announces That Lotus Has Submitted A New Drug Application To South Korea's Ministry Of Food And Drug Safety For Vizz, Intended To Treat Presbyopia In Adults
LENZ Therapeutics, Inc. (NASDAQ:LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced that Lotus has submitted a New Drug Application (NDA) to the Ministry of Food and Drug Safety
2025-12-01 21:33
LENZ Therapeutics shares are trading lower. The company reported Q3 financial results.
LENZ Therapeutics shares are trading lower. The company reported Q3 financial r...
2025-11-05 22:26
LENZ Therapeutics Q3 EPS $(0.59) Beats $(0.67) Estimate, Sales $12.500M Beat $6.828M Estimate
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(0.59) per share which beat the analyst consensus estimate of $(0.67) by 11.54 percent. This is a 55.26 percent decrease over losses of $(0.38) per share from
2025-11-05 21:06
LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025
LENZ Therapeutics will host a webcast on November 5, 2025, at 8:30 a.m. EST to discuss its third-quarter 2025 financial results and recent corporate updates. Participants can join via telephone using the provided numbers and code, or access the live webcast online at [www.LENZ-tx.com](https://www.globenewswire.com/Tracker?data=VKl91OEpK0WhJFPnCp6MwnPPNgip-sq5rjU408Sktjf4OnmEyXGIRo6cANW4mR4iqUQRzVBU2O2GNuezx-g15zzc_XyLQ1_FMIV0Ak706pk=). VIZZ™, the...
2025-10-29 12:00
美股大行评级 | 潜在涨幅344.44%！Rani Therapeutics获Maxim Group升目标价至10美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Rani Therapeutics Hldgs"买入"评级，目标价从5美元升至10美元；韦德布什：维持Corbus Pharmaceuticals"跑赢大市"评级，目标价从31美元升至38美元
2025-10-21 18:13
Raymond James Reiterates Outperform on LENZ Therapeutics, Raises Price Target to $50
Raymond James analyst Gary Nachman reiterates LENZ Therapeutics (NASDAQ:LENZ) with a Outperform and raises the price target from $40 to $50.
2025-10-21 01:18
美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
2025-10-13 11:26
